Transforming growth factor beta receptor II (TGFBR2)

Transforming growth factor beta receptor II is a transmembrane serine/threonine kinase that serves as an essential component in the transforming growth factor beta (TGF-beta) signaling pathway. It binds extracellular TGF-beta ligands via its N-terminal ectodomain. Upon ligand binding, it forms a heteromeric complex with type I receptors—this assembly triggers phosphorylation events that activate intracellular effectors such as SMAD proteins. The activated SMAD complexes then translocate into the nucleus where they regulate transcriptional programs controlling cell proliferation, differentiation, apoptosis, immune responses, wound healing processes, and maintenance of connective tissue homeostasis. Mutations or loss-of-function alterations in this gene are implicated in various human diseases including hereditary cancers like colorectal cancer with microsatellite instability; connective tissue disorders such as Marfan syndrome and Loeys-Dietz syndrome; vascular abnormalities; and other syndromic conditions. Due to its central regulatory role at multiple biological checkpoints—and context-dependent function switching between tumor suppression at early stages versus promotion at later stages—therapeutically modulating this target presents both opportunities and significant challenges.

Other names

TGF-beta receptor type 2TGF-beta RIITGFβRIITGFR2

Drugs or biologics that interact with this target typically act by one or more of the following mechanisms: - Inhibition of ligand binding to prevent activation of the receptor complex - Blockade of serine/threonine kinase activity to inhibit downstream SMAD phosphorylation and signal transduction - Disruption of heterodimerization with type I receptors to block canonical signaling pathways